Suchergebnisse - "Yeh, Teng-Kuang"

PubPharm (8)

1

Design and synthesis of novel orally selective and type II pan-TRK inhibitors to overcome mutations by property-driven optimization

enthalten in: European journal of medicinal chemistry | 2021

von Li, M. | Lin, W. | Wang, P. | +10

2

Discovery and Synthesis of a Pyrimidine-Based Aurora Kinase Inhibitor to Reduce Levels of MYC Oncoproteins

enthalten in: Journal of medicinal chemistry | 2021

von Chi, Y. | Yeh, T. | Ke, Y. | +17

3

Drug-like property optimization : Discovery of orally bioavailable quinazoline-based multi-targeted kinase inhibitors

enthalten in: Bioorganic chemistry | 2020

von Lin, S. | Chang, C. | Coumar, M. | +14

4

Discovery of BPR1K871, a quinazoline based, multi-kinase inhibitor for the treatment of AML and solid tumors : Rational design, synthesis, in vitro and in vivo evaluation

enthalten in: Oncotarget | 2016

von Hsu, Y. | Coumar, M. | Wang, W. | +22

5

2-Aroylquinoline-5,8-diones as potent anticancer agents displaying tubulin and heat shock protein 90 (HSP90) inhibition

enthalten in: Organic & biomolecular chemistry | 2016

von Nepali, K. | Kumar, S. | Huang, H. | +8

ErratumIn: Org Biomol Chem. 2018 Jul 7;16(25):4734. - PMID 29904758

6

Novel Nrf2/ARE activator, trans-Coniferylaldehyde, induces a HO-1-mediated defense mechanism through a dual p38α/MAPKAPK-2 and PK-N3 signaling pathway

enthalten in: Chemical research in toxicology | 2015

von Chen, H. | Wang, T. | Lee, Y. | +12

7

3D-QSAR-assisted drug design : identification of a potent quinazoline-based Aurora kinase inhibitor

enthalten in: ChemMedChem | 2013

von Ke, Y. | Shiao, H. | Hsu, Y. | +12

8

BPR1K653, a novel Aurora kinase inhibitor, exhibits potent anti-proliferative activity in MDR1 (P-gp170)-mediated multidrug-resistant cancer cells

enthalten in: PloS one | 2011

von Cheung, C. | Lin, W. | Hsu, J. | +11

1
[1]